Corteriapharma

7 known investors

Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications. Its pipeline includes a CRF2 peptide agonist and a vasopressin neutralizing antibody, and it uses patient stratification based on human evidence and disease biology.